Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week brexpiprazole extension study in agitation associated with Alzheimer's dementia
2018-002783-88Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Frequency and severity of adverse events. Started Oct 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-002783-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002783-88.